About Sex comb on midleg-like protein 4
Sex comb on midleg-like protein 4 (SCML4) is a protein
from Homo sapiens identified by UniProt accession
Q8N228, 414 residues long.
MolForge cross-references it against 0 known binders and
44 disease associations.
Target properties
| Protein name | Sex comb on midleg-like protein 4 |
| UniProt accession | Q8N228 |
| Gene | SCML4 |
| Organism | Homo sapiens |
| Length | 414 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (44)
Diseases linked to this target (Open Targets).
- lymphocyte count · score 0.52
- lymphocyte percentage of leukocytes · score 0.47
- neutrophil percentage of leukocytes · score 0.47
- self reported educational attainment · score 0.43
- neutrophil-to-lymphocyte ratio · score 0.42
- lymphocyte:monocyte ratio · score 0.34
- protein measurement · score 0.32
- pathological myopia · score 0.32
- coronary artery disease · score 0.31
- mathematical ability · score 0.30
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q8N228-F1 | alphafold | PREDICTED | 68.96 | — |
Amino-acid sequence (414 residues)
MQSQRIPGRK RGRPSLHSTP MKMAVHNLYS ASAGSLPAVK IPKKRGRKPG YKIKSRVLMT PLALSPPRST PEPDLSSIPQ DAATVPSLAA PQALTVCLYI NKQANAGPYL ERKKVQQLPE HFGPERPSAV LQQAVQACID CAHQQKLVFS LVKQGYGGEM VSVSASFDGK QHLRSLPVVN SIGYVLRFLA KLCRSLLCDD LFSHQPFPRG CSASEKVQEK EEGRMESVKT VTTEEYLVNP VGMNRYSVDT SASTFNHRGS LHPSSSLYCK RQNSGDSHLG GGPAATAGGP RTSPMSSGGP SAPGLRPPAS SPKRNTTSLE GNRCASSPSQ DAQDARRPRS RNPSAWTVED VVWFVKDADP QALGPHVELF RKHEIDGNAL LLLKSDMVMK YLGLKLGPAL KLCYHIDKLK QAKF
Explore Sex comb on midleg-like protein 4 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets